Table 3.
Inflammasome interventions in tumor-related clinical trials
| Interventions related to inflammasomes | Diseases | Stage of development | Comments | NCT numbers |
|---|---|---|---|---|
| Glycyrrhizin | Lung cancer | I/II (completed) | NLRP3 inhibitor | NCT02449122 |
| Liver cancer | I/II (completed) | NLRP3 inhibitor | NCT02449109 | |
| ACT001 | Glioblastoma | I/II (recruiting) | NLRP3 inhibitor | NCT05053880 |
| Andrographolides | Colon cancer | II (terminated) | NLRP3/AIM2 inhibitor | NCT01993472 |
| Methylene Blue | Colon cancer | III (completed) | broad-spectrum inflammasome inhibitor | NCT01694966 |
| Methylene blue | Breast cancer | Not Applicable | broad-spectrum inflammasome inhibitor | NCT02084784 |
| BMS-986299 | Advanced cancer | I (terminated) | NLRP3 activator | NCT03444753 |
| Thalidomide | Prostate cancer | II (completed) | caspase-1 inhibitor | NCT00400517 |
| Thalidomide | Multiple myeloma | III (completed) | caspase-1 inhibitor | NCT01296503 |
| Canakinumab | Lung cancer | III (completed) | IL-1β inhibitor | NCT01327846 |
| Canakinumab | Lung cancer | III (active, not recruiting) | IL-1β inhibitor | NCT 03,447,769 |
| Canakinumab | Lung cancer | II (recruiting) | IL-1β inhibitor | NCT04905316 |
| Canakinumab | Lung cancer | III (active, not recruiting) | IL-1β inhibitor | NCT03631199 |
| Canakinumab | Lung cancer | II (completed) | IL-1β inhibitor | NCT 03,968,419 |
| Canakinumab | Lung cancer | II (recruiting) | IL-1β inhibitor | NCT04789681 |
| Canakinumab | Lung cancer | III (completed) | IL-1β inhibitor | NCT03626545 |
| Canakinumab | Lung cancer | I (terminated) | IL-1β inhibitor | NCT03064854 |
| Canakinumab | Lung cancer, breast cancer, colon cancer | I (completed) | IL-1β inhibitor | NCT02900664 |
| Canakinumab | Pancreatic cancer | I (active, not recruiting) | IL-1β inhibitor | NCT04581343 |
| Canakinumab | Pancreatic cancer | III (recruiting) | IL-1β inhibitor | NCT04229004 |
| Canakinumab | Breast cancer | I (active, not recruiting) | IL-1β inhibitor | NCT03742349 |
| Canakinumab | Myelodysplastic syndromes and chronic myelomonocytic leukemia | II (recruiting) | IL-1β inhibitor | NCT04239157 |
| Canakinumab | Myelodysplastic syndromes | II (recruiting) | IL-1β inhibitor | NCT05237713 |
| Canakinumab | Myelodysplastic syndromes | I/II (recruiting) | IL-1β inhibitor | NCT04798339 |
| Canakinumab | Myelodysplastic syndromes | I (recruiting) | IL-1β inhibitor | NCT04810611 |
| Canakinumab | Renal cancer | Early Phase 1 (recruiting) | IL-1β inhibitor | NCT04028245 |
| Canakinumab | Melanoma | II (active, not recruiting) | IL-1β inhibitor | NCT03484923 |
| Canakinumab | Clonal cytopenias of unknown significance | II (recruiting) | IL-1β inhibitor | NCT05641831 |
| Gevokizumab | Colon cancer | I (active, not recruiting) | IL-1β inhibitor | NCT03798626 |
| Tadekinig alfa (IL-18BP) | CAR T-cell-related cytokine release syndrome | Early Phase 1 (recruiting) | IL-18 inhibitor | NCT05306080 |
| Xilonix | Colon cancer | III (terminated) | IL-1α inhibitor | NCT01767857 |
| Xilonix | Colon cancer | III (completed) | IL-1α inhibitor | NCT02138422 |
| Xilonix | Pancreatic cancer | I (completed) | IL-1α inhibitor | NCT03207724 |
| Xilonix | Advanced cancer | I (completed) | IL-1α inhibitor | NCT01021072 |
| SB-485232 | Ovarian cancer | I (completed) | Recombinant IL-18 | NCT00659178 |
| SB-485232 | Melanoma | II (completed) | Recombinant IL-18 | NCT00107718 |
| SB-485232 | Lymphoma | I (completed) | Recombinant IL-18 | NCT00500058 |
| SB-485232 | Lymphoma | I (completed) | Recombinant IL-18 | NCT01768338 |
| SB-485232 | Solid tumor | I (completed) | Recombinant IL-18 | NCT00085878 |
| SB-485232 | Solid tumor and lymphoma | I (completed) | Recombinant IL-18 | NCT00085904 |
| ST-067 | Solid tumor | I/II (recruiting) | Recombinant IL-18 | NCT04787042 |
| huCART19-IL18 | Leukemia and lymphoma | I (recruiting) | CAR-T targeting CD19 and expressing IL-18 | NCT04684563 |
| Anakinra | Breast cancer | I (completed) | IL-1 receptor inhibitor | NCT01802970 |
| Anakinra | Rectal cancer | I (recruiting) | IL-1 receptor inhibitor | NCT04942626 |
| Anakinra | Colon cancer | II (completed) | IL-1 receptor inhibitor | NCT02090101 |
| Anakinra | Pancreatic cancer | I (unknown) | IL-1 receptor inhibitor | NCT02021422 |
| Anakinra | Pancreatic cancer | Early I (completed) | IL-1 receptor inhibitor | NCT02550327 |
| Anakinra | Pancreatic cancer | II (not yet recruiting) | IL-1 receptor inhibitor | NCT04926467 |
| Anakinra | Prostate cancer | I (active, not recruiting) | IL-1 receptor inhibitor | NCT04227275 |
| Anakinra | Multiple myeloma and plasma cell neoplasm | II (completed) | IL-1 receptor inhibitor | NCT00635154 |
| Anakinra | Multiple myeloma | I/II (active, not recruiting) | IL-1 receptor inhibitor | NCT03430011 |
| Anakinra | Multiple myeloma | II (completed) | IL-1 receptor inhibitor | NCT03233776 |
| Anakinra | Multiple myeloma | II (recruiting) | IL-1 receptor inhibitor | NCT04099901 |
| Anakinra | Myeloma | I (completed) | IL-1 receptor inhibitor | NCT02492750 |
| Anakinra | B-cell lymphoma | II (active, not recruiting) | IL-1 receptor inhibitor | NCT04432506 |
| Anakinra | B-cell lymphoma | II (recruiting) | IL-1 receptor inhibitor | NCT04359784 |
| Anakinra | B-cell lymphoma | II (recruiting) | IL-1 receptor inhibitor | NCT04205838 |
| Anakinra | Lymphoma | II (active, not recruiting) | IL-1 receptor inhibitor | NCT04150913 |
| Anakinra | B-cell lymphoma/leukemia | II (recruiting) | IL-1 receptor inhibitor | NCT04148430 |
| Anakinra | Chronic lymphocytic leukemia | I (unknown) | IL-1 receptor inhibitor | NCT04691765 |
| Anakinra | Solid tumor | I (completed) | IL-1 receptor inhibitor | NCT00072111 |
| Anakinra | Advanced Cancer | I (completed) | IL-1 receptor inhibitor | NCT01624766 |